Bristol-Myers Squibb Company
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BMYB34.SA | ABBV | LLY | BIIB | AMGN | GILD | |
|---|---|---|---|---|---|---|
| Market cap | 696.42B | 521.00B | 1.26T | 37.61B | 258.68B | 216.41B |
| P/E (TTM) | 14.5 | 50.7 | 46.0 | 110.2 | 27.7 | — |
| Forward P/E | — | 18.2 | 28.3 | 15.6 | 19.5 | 17.3 |
| Price/book | 5.9 | -113.7 | 31.4 | 2.0 | 18.0 | 16.6 |
| Dividend yield | 3.81% | 2.35% | 0.49% | — | 2.11% | 1.88% |
| 1-year change | +37.01% | +34.60% | +51.26% | +62.35% | +51.61% | +41.39% |
| Today | 0.00% | +3.09% | +0.61% | +2.22% | +3.73% | +4.19% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 15 min.
Latest news
All BMYB34.SA news ›Bristol Myers Squibb confirms patient death in multiple sclerosis CAR T trial
BMS halted the study earlier this year following three patient deaths in a competitor’s trial. “Although the patient’s CAR T cell expansion was consistent with that observed across the study, high-dose cyclophosphamide was administered,…
Could You Have Seen The Run In Bristol Myers Squibb Stock Coming?
Management Flagged Growth Portfolio Sales In Early 2025 During its February 6, 2025 call to discuss the fourth quarter of 2024, management said the growth portfolio had grown revenue at double digits. On the April 24, 2025 call, the…
Barclays Keeps Their Buy Rating on Bristol-Myers Squibb (BMY)
In a report released today, Emily Field from Barclays maintained a Buy rating on Bristol-Myers Squibb, with a price target of $75.00. Field covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and…
Bristol Myers Squibb Q3 Earnings Call Highlights
Posted by Danessa Lincoln on Oct 31st, 2026 Bristol Myers Squibb (NYSE:BMY) raised its full-year 2026 outlook after reporting third-quarter revenue growth supported by its growth portfolio and continued strength in ELIQUIS, while outlining…
More from 4 other outlets
- The Motley Fool Bristol-Myers Squibb (BMY) Q3 2026 Earnings Call Transcript
- Seeking Alpha Bristol-Myers Squibb Company (BMY) Q3 2026 Earnings Call Transcript
- singjupost.com Bristol Myers Squibb (BMY) Q3 2026 Earnings Call Transcript
- FinancialContent Bristol-Myers Squibb (BMY) Q3 earnings: what to expect
Bristol-Myers Squibb: Progress On The Bridge, But The Patent Cliffs Remain (Rating Downgrade)
Bristol-Myers Squibb is downgraded to Hold as its current valuation appears optimistic ahead of looming patent cliffs. Read more on BMY stock here. - Bristol-Myers Squibb is downgraded to 'Hold' as its current valuation appears optimistic…
Birinyi Associates Inc. Purchases New Position in Bristol Myers Squibb Company $BMY
Check Out Our Latest Analysis on BMY The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a dividend of $0.63 per share. This…
Bristol Myers Squibb Company $BMY Stock Bought by Americana Partners LLC
Posted by Sarita Garza on Oct 31st, 2026 The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be given a $0.63 dividend. The ex-dividend date…
Bristol-Myers Squibb Beat Estimates but Cut EPS Guidance in Q3 2026
As seen on the 24/7 Wall St. homepage on October 29, 2026. Bristol Myers Squibb cut full-year adjusted EPS guidance to $6.35 to $6.55 from $6.75 to $7.00 even though both lines topped expectations, a split driven by acquired IPRD charges…
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026
Bristol Myers Squibb (NYSE: BMY) today reported third quarter 2026 financial results. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, October 29, 2026, which is accessible…
More from 1 other outlet
Bristol Myers Squibb Co. Q3 Income Retreats
Bristol Myers Squibb Co. (BMY) released a profit for third quarter that Drops, from the same period last year The company's bottom line totaled $2.162 billion, or $1.05 per share. This compares with $2.201 billion, or $1.08 per share, last…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com23
- theglobeandmail.com20
- fool.com19
- marketbeat.com12
- themarketsdaily.com9
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.